Algeta appoints Dr. Donald Coppen as Business Development Director
Algeta ASA announced that it has appointed Donald Coppen as business development Director.
Dr. Coppen will join Chief Business Officer Roger Harrison in driving Algeta's business development strategy aimed at advancing its Thorium payload technology for creating novel targeted cancer therapies, and expanding the Company's pipeline of product candidates.
Dr. Coppen joins Algeta from Biocompatibles International (now part of BTG plc), a UK-based oncology company developing drug-device combination products, where he was Director, Partnering & Licensing. He has previously held project leadership and managerial roles at Lonza Biologics in the UK, and within the crop protection division of Cyanamid International, part of Wyeth (now Pfizer), in Belgium.
Dr. Coppen has a PhD from the University of Southampton and a MBA from the Cranfield School of Management.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
New coronavirus related to viruses from bats

Analytica 2022 wowed the laboratory industry - analytica extended: digital extension through July 8
Novel process for DNA labeling

Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial
Wolff's_law

Incurable liver disease may prove curable - Research has found a drug that can spur liver regeneration in Alagille syndrome: researcher taking Steps to form a start-up company
Thomson Reuters Predicts Nobel Laureates
Existing drug preserves insulin production in new Type 1 diabetes cases
Illumina and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil - Uncovering Mutations Found in Deadly Transmissible Cancer Could Help Conservation Efforts

When mothers shut down the fathers’ genes in the embryo - “With our work, we were able to highlight a unique aspect of biology, a slice of nature’s broad diversity”
